

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
27 May 2004 (27.05.2004)

PCT

(10) International Publication Number
WO 2004/043903 A1

(51) International Patent Classification⁷: C07C 217/62,
217/64, 323/32, C07D 275/04, 307/86, 333/54, 333/56,
A61K 31/381, 31/137, 31/343, 31/425, A61P 25/06,
25/18, 25/24

(21) International Application Number:
PCT/US2003/031513

(22) International Filing Date: 24 October 2003 (24.10.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/424,176 5 November 2002 (05.11.2002) US

(71) Applicant (for all designated States except US): ELI
LILLY AND COMPANY [US/US]; Lilly Corporate
Center, Indianapolis, IN 46285 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BOULET, Serge,
Louis [CA/US]; 10813 Windemere Boulevard, Fish-
ers, IN 46038 (US). FILLA, Sandra, Ann [US/US];
1542 Arborwoods Drive, Brownsburg, IN 46112 (US).
GALLAGHER, Peter, Thaddeus [GB/GB]; Eli Lilly
and Company Limited, Kingsclere Road, Basingstoke,
Hampshire RG21 2XA (GB). HUDZIAK, Kevin, John
[US/US]; 5944 Magnificent Lane, Indianapolis, IN 46234
(US). JOHANSSON, Anette, Margareta [SE/US];
6350 Brokenhurst Road, Indianapolis, IN 46220 (US).
KARANJAWALA, Rushad, E. [US/US]; 9732 Autumn
Way, Zionsville, IN 46077 (US). MASTERS, John,
Joseph [US/US]; 12047 Flint Stone Court, Fishers, IN
46038 (US). MATASSA, Victor [GB/DE]; Graffinity
Pharmaceuticals, Im Neuenheimer Feld 519, 69120
Heidelberg (DE). MATHES, Brian, Michael [US/US];
5335 Cotton Bay Drive West, Indianapolis, IN 46254

(US). RATHMELL, Richard, Edmund [GB/GB]; Eli
Lilly and Company Limited, Kingsclere Road, Bas-
ingstoke, Hampshire RG21 2XA (GB). WHATTON,
Maria, Ann [GB/GB]; Eli Lilly and Company Limited,
Kingsclere Road, Basingstoke, Hampshire RG21 2XA
(GB). WOLFE, Chad, Nolan [US/US]; 16096 Tenor
Way, Noblesville, IN 46060 (US).

(74) Agents: WELCH, Lawrence, T. et al.; Eli Lilly and Com-
pany, P.O. Box 6288, Indianapolis, IN 46206-6288 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT (util-
ity model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (util-
ity model), DE, DK (utility model), DK, DM, DZ, EC, EE
(utility model), EE, EG, ES, FI (utility model), FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN,
MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU,
SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,

[Continued on next page]

(54) Title: 3-ARYLOXY/THIO-2, 3-SUBSTITUTED PROPANAMINES AND THEIR USE IN INHIBITING SEROTONIN AND NOREPINEPHRINE REUPTAKE



(57) Abstract: There is provided a compound of formula (I) wherein A is selected from -O- and -S-; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl and C₁-C₄ alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from halo and C₁-C₄ alkyl, and C₂-C₈ alkyl, C₂-C₈ alkenyl, C₃-C₈ cycloalkyl and C₄-C₈ cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -CN and -CONH₂; Y is selected from phenyl, naphthyl, dihydrobenzothienyl, ben-

zothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, naphthyridyl, thienopyridyl, indanyl, 1,3-benzodioxolyl, benzothienyl, indolyl and benzofuranyl, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano; and when Y is indolyl it may be substituted or further substituted by an N-substituent selected from C₁-C₄ alkyl; Z is selected from OR₃ or F, wherein R₃ is selected from H, C₁-C₆ alkyl and phenyl C₁-C₆ alkyl; R₁ and R₂ are each independently H or C₁-C₄ alkyl; and pharmaceutically acceptable salts thereof with the proviso that when Y is optionally substituted phenyl or optionally substituted 1,3-benzodioxolyl and Z is OR₃ and X is optionally substituted phenyl then A is -S-.



MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,

ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.